Geoffrey Kim

发表

J. Moslehi, Todd R. Palmby, T. Force, 2016, JACC. Basic to translational science.

Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms

Martha Donoghue, P. Keegan, R. Pazdur, 2016, Clinical Cancer Research.

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Liang Zhao, Hui Zhang, Richard Pazdur, 2015, Clinical Cancer Research.

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.

B. Monk, Amy McKee, R. Pazdur, 2017, Gynecologic oncology.

Regulatory considerations on endpoints in ovarian cancer drug development

Amy McKee, R. Pazdur, Geoffrey Kim, 2017, Cancer.

Successes and Challenges of PARP Inhibitors in Cancer Therapy

Amy McKee, R. Pazdur, Geoffrey Kim, 2015, Front. Oncol..

U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non–Small Cell Lung Cancer

S. Khozin, K. Goldberg, R. Pazdur, 2017, Clinical Cancer Research.

Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition

M. Bertagnolli, L. Fashoyin-Aje, R. Pazdur, 2022, Nature Medicine.

U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapyâ•’NaÃ ̄ve Metastatic Castrationâ•’Resistant Prostate Cancer

R. Pazdur, Geoffrey Kim, Lijun Zhang, 2015 .

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis

G. Helmlinger, Geoffrey Kim, K. Peskov, 2020, Oncoimmunology.

Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle

P. Jänne, A. Shaw, Amy McKee, 2016, Clinical Cancer Research.

Decoding kinase-adverse event associations for small molecule kinase inhibitors

Amy McKee, Todd R. Palmby, Geoffrey Kim, 2022, Nature Communications.

U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.

R. Pazdur, Geoffrey Kim, Lijun Zhang, 2015, The Oncologist.

FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration.

L. Fashoyin-Aje, R. Pazdur, Geoffrey Kim, 2017 .

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs

Sarah E. Dorff, Amy McKee, R. Pazdur, 2016, Clinical Cancer Research.

Proteomic Profiling in Ovarian Cancer

E. Kohn, Geoffrey Kim, L. Minig, 2009, International Journal of Gynecologic Cancer.

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy

K. Goldberg, R. Pazdur, Todd R. Palmby, 2017, The oncologist.

FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation

Justin C. Earp, Amy McKee, R. Pazdur, 2014, Clinical Cancer Research.

FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers.

R. Pazdur, Geoffrey Kim, G. Blumenthal, 2016 .

L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer

E. Kohn, Minshu Yu, Geoffrey Kim, 2012, Journal of cellular and molecular medicine.

FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis

R. Pazdur, Geoffrey Kim, Lijun Zhang, 2017, The oncologist.

Proteomics and ovarian cancer: integrating proteomics information into clinical care.

E. Kohn, Geoffrey Kim, I. Giuroiu, 2010, Journal of proteomics.

Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome

E. Kohn, Junbai Wang, B. Davidson, 2012, Cancer.

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer

S. J. Schrieber, Chao Liu, Richard Pazdur, 2017, Clinical Cancer Research.

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Amy McKee, R. Pazdur, Todd R. Palmby, 2016, Clinical Cancer Research.

Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials

P. Keegan, R. Pazdur, Geoffrey Kim, 2015, Clinical Cancer Research.

U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.

R. Pazdur, Geoffrey Kim, Lijun Zhang, 2015, The oncologist.

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer

R. Pazdur, R. Charlab, Todd R. Palmby, 2015, Clinical Cancer Research.

21st Century Cardio-Oncology

J. Moslehi, Todd R. Palmby, T. Force, 2016, JACC. Basic to translational science.

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.

K. Goldberg, Amy McKee, R. Pazdur, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

C. Garnett, R. Pazdur, Y. Moon, 2012, Clinical Cancer Research.

Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials—Response

Martha Donoghue, P. Keegan, R. Pazdur, 2016, Clinical Cancer Research.

FDA analysis of patients with baseline autoimmune diseases treated with PD-1/PD-L1 immunotherapy agents.

R. Pazdur, Geoffrey Kim, H. Singh, 2017 .

U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma

Amy McKee, R. Pazdur, Todd R. Palmby, 2016, Clinical Cancer Research.

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.

S. Steinberg, E. Kohn, Jung-Min Lee, 2013, Molecular and clinical oncology.

Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors.

E. Kohn, L. Minasian, S. Prindiville, 2010 .

Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer

R. Pazdur, Geoffrey Kim, R. Sridhara, 2015, Bladder cancer.

FDA analysis of treatment beyond disease progression disease (PD) in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab vs. everolimus.

R. Pazdur, Geoffrey Kim, Lijun Zhang, 2016 .

Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology

D. Hyman, Geoffrey Kim, Yan Ji, 2018, Clinical and translational science.

Regulatory watch: Evaluating the potential for digital submission of expedited premarket safety reports to the FDA

S. Khozin, R. Pazdur, Geoffrey Kim, 2016, Nature Reviews Drug Discovery.

An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies

Richard Pazdur, Reena Philip, Reena Philip, 2016, Clinical Cancer Research.

Clinical Development of Cancer Drugs in Combination With External Beam Radiation Therapy: US Food and Drug Administration Perspective.

R. Pazdur, Geoffrey Kim, P. Kluetz, 2017, International journal of radiation oncology, biology, physics.